{"Content: ":"BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech,[1][2] American company Precision Virologics[3][4] and the Washington University School of Medicine in St Louis, Missouri, United States.[5][6] On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee's consideration before it proceeds to the second phase of the trial.[7] On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with BBV154 in healthy volunteers.[8]  This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.","Title":"BBV154 - Wikipedia","KeyID":"11183","URL":"https://en.wikipedia.org/wiki/BBV154"}